VivoSim regains Nasdaq equity compliance, discloses post-10-K cash inflows

VivoSim Labs said on August 4, 2026, it received notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires registrants to maintain a minimum stockholders' equity of $2.5 million.¹

The company also disclosed two cash-generating events that occurred after its fiscal year end. First, it received a $5.0 million milestone payment from Eli Lilly and Company, along with $1.0 million released from escrow on July 22, 2026, tied to its earlier sale of the FXR program to Eli Lilly.¹ Second, it closed a financing on July 17, 2026, selling pre-funded warrants and common warrants at $0.85 per underlying share, generating $4.0 million in gross proceeds and about $3.6 million net.¹

VivoSim noted these events happened too late to appear in its fiscal 2026 Form 10-K, filed July 14, 2026, and said they also will not show up in the upcoming Form 10-Q for the quarter ended June 30, 2026.¹ As a result, cash on hand as of August 3, 2026 stood at approximately $10.1 million.¹

Share count also shifted sharply after warrant exercises: shares outstanding rose from 3,194,295 on June 30, 2026 to 13,390,789 by August 3, 2026, reflecting 9,896,718 shares issued between July 15 and July 31, 2026 upon warrant exercises.¹

On the operating side, VivoSim reiterated guidance for more than 500% revenue growth in fiscal year 2027, citing progress marketing contract research services using its NAM models to pharmaceutical companies.¹ The company cautioned that the financial figures in the release are preliminary and unaudited, and should not be treated as a substitute for full GAAP financial statements.¹